Loading...
Market
Primary method of mpox transmission by end of 2024?
2
Resolution / Starting Odds
Human-to-human contact • 25%
Animal-to-human contact • 25%
Contaminated surfaces • 25%
Other • 25%
WHO reports and scientific studies
Story
WHO and Partners Establish Mechanism to Combat Global Mpox Outbreak with Vaccines, Treatments, and Tests
Sep 13, 2024, 11:50 AM
The World Health Organization (WHO) and its partners have established an Access and Allocation Mechanism (AAM) to address the global mpox outbreak. This initiative aims to increase access to mpox vaccines, treatments, and tests for people at highest risk and ensure that limited supplies are used effectively and equitably. In response to the international public health emergency, Cell Press has updated its policies regarding mpox manuscripts and made related content freely available. Urgent actions are needed to scale up testing and surveillance, study research gaps, invest in vaccines and therapeutics, and improve access to high-quality care.
View original story
Similar markets
Human-to-human contact • 25%
Animal-to-human contact • 25%
Environmental exposure • 25%
Other/Unknown • 25%
Human-to-Human Contact • 25%
Animal-to-Human Contact • 25%
Contaminated Objects • 25%
Other • 25%
Human-to-human transmission • 25%
Animal-to-human transmission • 25%
Unknown • 25%
Other • 25%
Sexual networks • 25%
Household transmission • 25%
Healthcare settings • 25%
Other • 25%
Human-to-human contact • 25%
Animal-to-human transmission • 25%
Environmental exposure • 25%
Unknown/Other • 25%
Travel-related • 25%
Community spread • 25%
Animal transmission • 25%
Unknown • 25%
Animal-to-human • 25%
Human-to-human • 25%
Environmental • 25%
Unknown • 25%
Vaccination campaigns • 25%
Travel restrictions • 25%
Public awareness programs • 25%
Quarantine and isolation • 25%
Less than 5,000 • 25%
5,000 to 10,000 • 25%
10,001 to 20,000 • 25%
More than 20,000 • 25%
Africa Only • 25%
Africa and Asia • 25%
Africa, Asia, and Europe • 25%
Global • 25%
Human-to-human contact • 25%
Animal-to-human contact • 25%
Environmental exposure • 25%
Unclear/Other • 25%
Tecovirimat • 25%
New antiviral drug • 25%
Supportive care only • 25%
Combination therapy • 25%